For no particular reason, monoclonal antibodies as therapy for for Alzheimer's (e.g., lecanemab, aducanumab) can cause immune-mediated reactions, including skin rashes and pruritus…
Just sayin’
Just sayin’
A new rash on the right side of President Donald Trump’s neck is the result of a cream that he’s using as a “preventative skin treatment,” his personal physician told CNN on Monday.
Trump’s neck rash is because of ‘preventative skin treatment,’ his doctor says | CNN Politics
A new rash on the right side of President Donald Trump’s neck is the result of a cream that he’s using as a “preventative skin treatment,” his personal physician told CNN on Monday.
cnn.it
March 3, 2026 at 12:22 AM
For no particular reason, monoclonal antibodies as therapy for for Alzheimer's (e.g., lecanemab, aducanumab) can cause immune-mediated reactions, including skin rashes and pruritus…
Just sayin’
Just sayin’
So, I was deep-diving some more on that Aducanumab, the Alzheimer’s drug, & the MOCA test.
I am 100% certain Chump is on Aducanumab, a treatment for Alzheimer’s. Everything lines up & our government IS LYING TO US. Surprise!🤦🏻♀️
Watch this young man’s video about the MOCA test.
youtu.be/21uUp7wSXxM?...
I am 100% certain Chump is on Aducanumab, a treatment for Alzheimer’s. Everything lines up & our government IS LYING TO US. Surprise!🤦🏻♀️
Watch this young man’s video about the MOCA test.
youtu.be/21uUp7wSXxM?...
December 21, 2025 at 9:11 PM
So, I was deep-diving some more on that Aducanumab, the Alzheimer’s drug, & the MOCA test.
I am 100% certain Chump is on Aducanumab, a treatment for Alzheimer’s. Everything lines up & our government IS LYING TO US. Surprise!🤦🏻♀️
Watch this young man’s video about the MOCA test.
youtu.be/21uUp7wSXxM?...
I am 100% certain Chump is on Aducanumab, a treatment for Alzheimer’s. Everything lines up & our government IS LYING TO US. Surprise!🤦🏻♀️
Watch this young man’s video about the MOCA test.
youtu.be/21uUp7wSXxM?...
Success! We've now run almost 2000 mouse cortex and plasma samples through this assay so expect more publications referencing it very soon. Much thanks to the Skyline team and @maccoss.bsky.social #modelad #teammassspec #proteomics www.tandfonline.com/doi/full/10....
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab
A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyl...
www.tandfonline.com
July 25, 2025 at 7:16 PM
Success! We've now run almost 2000 mouse cortex and plasma samples through this assay so expect more publications referencing it very soon. Much thanks to the Skyline team and @maccoss.bsky.social #modelad #teammassspec #proteomics www.tandfonline.com/doi/full/10....
Dementia experts are optimistic about fresh treatments since the development of Aducanumab but do not want to raise false hopes of a possible cure
New Alzheimer’s drugs are coming. How excited should we be?
Dementia experts are optimistic about fresh treatments since the development of Aducanumab but do not want to raise false hopes of a possible cure
www.thetimes.com
August 22, 2025 at 3:32 PM
Dementia experts are optimistic about fresh treatments since the development of Aducanumab but do not want to raise false hopes of a possible cure
🚨New in Lancet Neurology: Autopsy study of aducanumab in #Alzheimer’s shows superficial cortical Aβ cleared, but deeper persists. ARIA showed inflammation+ microinfarcts in leptomeningeal/penetrating vessels. Some path is PET-invisible. @drneurochic.bsky.social
authors.elsevier.com/a/1lxn85FFzL...
authors.elsevier.com/a/1lxn85FFzL...
October 16, 2025 at 10:33 AM
🚨New in Lancet Neurology: Autopsy study of aducanumab in #Alzheimer’s shows superficial cortical Aβ cleared, but deeper persists. ARIA showed inflammation+ microinfarcts in leptomeningeal/penetrating vessels. Some path is PET-invisible. @drneurochic.bsky.social
authors.elsevier.com/a/1lxn85FFzL...
authors.elsevier.com/a/1lxn85FFzL...
The “promised cures have fizzled” is a link to an article about the biologic therapeutic aducanumab, which targets beta-amyloid “plaques” in Alzheimer's patients. The main problem there is a still insufficient basic scientific understanding of the mechanism behind neurodegenerative etiologies
/3c
/3c
September 22, 2025 at 2:56 PM
The “promised cures have fizzled” is a link to an article about the biologic therapeutic aducanumab, which targets beta-amyloid “plaques” in Alzheimer's patients. The main problem there is a still insufficient basic scientific understanding of the mechanism behind neurodegenerative etiologies
/3c
/3c
Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies #NeuroDegeneration 🧪🧠
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71758?af=R
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71758?af=R
October 8, 2026 at 10:05 AM
Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies #NeuroDegeneration 🧪🧠
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71758?af=R
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71758?af=R
I'm saying the Vioxx approval resulted from an agency culture that strongly suppressed safety signals and warnings, that the agency culture has not sufficiently been addressed, that recent approvals like aducanumab, lecanemab and donanemab demonstrate the problem is still a problem,
July 26, 2024 at 6:19 PM
I'm saying the Vioxx approval resulted from an agency culture that strongly suppressed safety signals and warnings, that the agency culture has not sufficiently been addressed, that recent approvals like aducanumab, lecanemab and donanemab demonstrate the problem is still a problem,
the risks include brain edema & little brain bleeds.
the first one that was approved, aducanumab, was withdrawn in the us once other options were available
would i do it if i had mci & met criteria? maybe. more time at home means more time to close out & less ltc cost to family
the first one that was approved, aducanumab, was withdrawn in the us once other options were available
would i do it if i had mci & met criteria? maybe. more time at home means more time to close out & less ltc cost to family
April 4, 2026 at 11:34 PM
the risks include brain edema & little brain bleeds.
the first one that was approved, aducanumab, was withdrawn in the us once other options were available
would i do it if i had mci & met criteria? maybe. more time at home means more time to close out & less ltc cost to family
the first one that was approved, aducanumab, was withdrawn in the us once other options were available
would i do it if i had mci & met criteria? maybe. more time at home means more time to close out & less ltc cost to family
That breakthrough drug to treat it that was approved a few years ago? Doesn't actually do shit for Alzheimer's, *does* have major and devastating side effects, and was approved over the recommendations of 10/11 members of the panel, most of whom resigned in protest: time.com/6081333/biog...
Doctors Remain Divided Over First Drug to Treat Alzheimer’s, But Patients Are Eager to Try It
The FDA approved Biogen's Aduhelm (aducanumab), the first treatment for Alzheimer's Disease—but it won’t be easy for patients to get it.
time.com
September 2, 2024 at 9:54 PM
That breakthrough drug to treat it that was approved a few years ago? Doesn't actually do shit for Alzheimer's, *does* have major and devastating side effects, and was approved over the recommendations of 10/11 members of the panel, most of whom resigned in protest: time.com/6081333/biog...
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease
INTRODUCTION The monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab were developed for the treatment of Alzheimer's disease (AD). METHODS We used single-molecule detection an...
alz-journals.onlinelibrary.wiley.com
April 17, 2025 at 9:32 AM
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Wasn't the FDA already doing this? re: aducanumab and andexanet Alfa accelerated approval. Neither ended well, and everyone knew it was going to end badly from the moment of approval
June 6, 2025 at 12:12 AM
Wasn't the FDA already doing this? re: aducanumab and andexanet Alfa accelerated approval. Neither ended well, and everyone knew it was going to end badly from the moment of approval
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
INTRODUCTION The phase 3, open-label TRAILBLAZER-ALZ 4 study compared the effect of donanemab versus aducanumab on amyloid plaque (AP) clearance in participants with early symptomatic Alzheimer's di...
alz-journals.onlinelibrary.wiley.com
May 20, 2025 at 12:43 PM
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
I also explain how this mechanism, if in place in 2021, could have allowed the entry of #aducanumab into Canada. A drug USFDA approved for Alzheimer's disease but which our regulator + the European Medicines Agency effectively rejected due to its poor effectiveness and significant safety risks.
January 19, 2026 at 3:05 PM
I also explain how this mechanism, if in place in 2021, could have allowed the entry of #aducanumab into Canada. A drug USFDA approved for Alzheimer's disease but which our regulator + the European Medicines Agency effectively rejected due to its poor effectiveness and significant safety risks.
An eye-opener about flawed research into curing Alzheimer's with medicines that attack amyloid-β.
Despite failing to show benefits in two large, double-blind, placebo-controlled phase III trials in 2019, Aducanumab was approved by the FDA. Further drugs were approved despite showing no benefit.
Despite failing to show benefits in two large, double-blind, placebo-controlled phase III trials in 2019, Aducanumab was approved by the FDA. Further drugs were approved despite showing no benefit.
It's worthwhile to educate the broader public on this, but I'm sorry that this article gave so little credit to @charlespiller.bsky.social (and essentially none to Matthew Schrag and others) who relentlessly documented these concerns, at great reputational risk.
arstechnica.com/science/2026...
arstechnica.com/science/2026...
What’s the deal with Alzheimer’s disease and amyloid?
For decades, scientists have concentrated on what now looks to be a blind alley.
arstechnica.com
April 16, 2026 at 5:15 PM
An eye-opener about flawed research into curing Alzheimer's with medicines that attack amyloid-β.
Despite failing to show benefits in two large, double-blind, placebo-controlled phase III trials in 2019, Aducanumab was approved by the FDA. Further drugs were approved despite showing no benefit.
Despite failing to show benefits in two large, double-blind, placebo-controlled phase III trials in 2019, Aducanumab was approved by the FDA. Further drugs were approved despite showing no benefit.
3/ Three drugs targeting amyloid have now been approved: aducanumab (2021), lecanemab (2023), and donanemab (2024). Their modest success suggests amyloid plays a role - but scientists increasingly believe it's just one piece of the puzzle.
January 7, 2025 at 3:02 PM
3/ Three drugs targeting amyloid have now been approved: aducanumab (2021), lecanemab (2023), and donanemab (2024). Their modest success suggests amyloid plays a role - but scientists increasingly believe it's just one piece of the puzzle.
With the EMA's unfortunate reversal on lecanemab here's a condensed (anti)anti-amyloid antibody argument: 1) No correlation between amyloid removal and clinical response 2) Functional unblinding may explain much/all of the "response" 3) No effect on tau.
pubmed.ncbi.nlm.nih.gov/38250779/🧪#alzskyky
pubmed.ncbi.nlm.nih.gov/38250779/🧪#alzskyky
Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies - PubMed
With the FDA approval of aducanumab and lecanemab, and with the recent statistically significant phase 3 clinical trial for donanemab, there is growing enthusiasm for anti-amyloid antibodies in the tr...
pubmed.ncbi.nlm.nih.gov
November 19, 2024 at 10:54 PM
With the EMA's unfortunate reversal on lecanemab here's a condensed (anti)anti-amyloid antibody argument: 1) No correlation between amyloid removal and clinical response 2) Functional unblinding may explain much/all of the "response" 3) No effect on tau.
pubmed.ncbi.nlm.nih.gov/38250779/🧪#alzskyky
pubmed.ncbi.nlm.nih.gov/38250779/🧪#alzskyky
Instead, I worry that this kind of process will be used by sponsors of new drugs that have been fast tracked in other countries, such as #aducanumab (often on the basis of surrogate endpoints) and have limited evidence of effectiveness but high prices.
January 19, 2026 at 3:05 PM
Instead, I worry that this kind of process will be used by sponsors of new drugs that have been fast tracked in other countries, such as #aducanumab (often on the basis of surrogate endpoints) and have limited evidence of effectiveness but high prices.
Presented at #AAIC26:
#Amyloid clearance was most efficient in gyral crests, not sulcal depths, and correlated locally with reduced #tau #pathology and #neurodegeneration after aducanumab therapy in #AlzheimerDisease.
ja.ma/4yiSchb
#Amyloid clearance was most efficient in gyral crests, not sulcal depths, and correlated locally with reduced #tau #pathology and #neurodegeneration after aducanumab therapy in #AlzheimerDisease.
ja.ma/4yiSchb
July 12, 2026 at 4:15 PM
Presented at #AAIC26:
#Amyloid clearance was most efficient in gyral crests, not sulcal depths, and correlated locally with reduced #tau #pathology and #neurodegeneration after aducanumab therapy in #AlzheimerDisease.
ja.ma/4yiSchb
#Amyloid clearance was most efficient in gyral crests, not sulcal depths, and correlated locally with reduced #tau #pathology and #neurodegeneration after aducanumab therapy in #AlzheimerDisease.
ja.ma/4yiSchb
journal backed by alz.org which is the same group that lobbied for aducanumab despite ??? clinical markers
i'm thinking there might be something rotten here specifically
i'm thinking there might be something rotten here specifically
April 30, 2026 at 5:16 PM
journal backed by alz.org which is the same group that lobbied for aducanumab despite ??? clinical markers
i'm thinking there might be something rotten here specifically
i'm thinking there might be something rotten here specifically
Aducanumab reduces plaques and other pathologies but significantly increases vascular Aβ deposits. Seems that whether you clear plaques or limit plaque deposition (via microglial depletion in vivo pre-plaque deposition), the consequence is vascular Aβ deposits 🤨 www.alzforum.org/news/confere...
Amyloid Immunotherapy Affects Multiple Alzheimer’s Pathologies | ALZFORUM
www.alzforum.org
December 22, 2025 at 7:58 PM
Aducanumab reduces plaques and other pathologies but significantly increases vascular Aβ deposits. Seems that whether you clear plaques or limit plaque deposition (via microglial depletion in vivo pre-plaque deposition), the consequence is vascular Aβ deposits 🤨 www.alzforum.org/news/confere...
It’s from the IV line for the aducanumab infusions.
April 30, 2026 at 9:40 PM
It’s from the IV line for the aducanumab infusions.
We live in extraordinary times.
The FDA has approved Biogen’s controversial Alzhimer’s treatment aducanumab.
https://www.fiercepharma.com/pharma/biogen-fda-aducanumab-decision
The FDA has approved Biogen’s controversial Alzhimer’s treatment aducanumab.
https://www.fiercepharma.com/pharma/biogen-fda-aducanumab-decision
November 26, 2024 at 1:37 PM
We live in extraordinary times.
The FDA has approved Biogen’s controversial Alzhimer’s treatment aducanumab.
https://www.fiercepharma.com/pharma/biogen-fda-aducanumab-decision
The FDA has approved Biogen’s controversial Alzhimer’s treatment aducanumab.
https://www.fiercepharma.com/pharma/biogen-fda-aducanumab-decision
#MedNews - Treatment with the anti-amyloid-β antibody #aducanumab clears amyloid from superficial cortical layers more than in deeper tissue.
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
Aducanumab amyloid-β-clearing strongest in superficial cortex
Treatment with the anti-amyloid-β antibody aducanumab clears amyloid from superficial cortical layers more than in deeper tissue.
www.springermedicine.com
October 28, 2025 at 11:54 AM
#MedNews - Treatment with the anti-amyloid-β antibody #aducanumab clears amyloid from superficial cortical layers more than in deeper tissue.
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
Full story 👉 buff.ly/XLteVb3
#NeuroSky #Alzheimers
Microglia on the move! Here’s microglial clustering around amyloid plaques (cyan) after one week of aducanumab treatment. Our new preprint shows this response begins within 18–48 hours. Pretty exciting to watch it unfold in the living brain!
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
September 12, 2026 at 1:56 PM
Microglia on the move! Here’s microglial clustering around amyloid plaques (cyan) after one week of aducanumab treatment. Our new preprint shows this response begins within 18–48 hours. Pretty exciting to watch it unfold in the living brain!
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...